A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-01-20Actual
Enrollment · participants153Actual
Source updated2025-12-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.